newsfilter
← Latest News
Business Wire·

InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

Topline data expected to be reported in Q1 2023 InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has